Improving risk prediction focusing on intermediate endpoints. Arterial stiffness. Pr. Stéphane LAURENT, MD, PhD, FESC
|
|
- Ruth Gwendolyn Dawson
- 6 years ago
- Views:
Transcription
1 Improving risk prediction focusing on intermediate endpoints Arterial stiffness Pr. Stéphane LAURENT, MD, PhD, FESC Pharmacology Department, Hôpital Européen Georges Pompidou, Paris Cardiovascular Research Center (P.A.R.C.C.), INSERM U970 Université Paris Descartes, Assistance Publique-Hôpitaux de Paris
2 DISCLOSURE Stéphane LAURENT, MD, PhD Potential conflict of interest: Research grant, advisory board, honorarium as speaker or chairman Drug companies ASTRA-ZENECA BAYER-SCHERING BOEHRINGER-INGELHEIM CHIESI DAICHII-SANKYO ESTEVE MENARINI MSD NEGMA NOVARTIS PFIZER RECORDATI SERVIER Manufacturers ALAM MEDICAL ATCOR ESAOTE-PIE MEDICAL HEMO SAPIENS OMRON TENSIOMED
3 Circulation 2011 Genetic and Environmental Risk factors Subclinical disease Imaging biomarkers (arterial stiffness, )
4 Clinical application of imaging biomarkers as. Intermediate endpoint or Surrogate endpoint?
5 NIH Biomarkers Definitions Working Group, Clin Pharmacol Therap, 2001;69:89-95 Definition A surrogate end point - is a subset of biomarkers - is «a biomarker that is intended to substitute for a clinical end point» and not for a marker. Thus, the term «surrogate marker» has been discouraged. - is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiological, therapeutic, pathophysiologic, or other scientific evidence. - applies primarily to therapeutic intervention trials
6 NIH Biomarkers Definitions Working Group, Clin Pharmacol Therap, 2001;69:89-95 Definition A surrogate end point - is a subset of biomarkers - is «a biomarker that is intended to substitute for a clinical end point» and not for a marker. Thus, the term «surrogate marker» has been discouraged. - is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiological, therapeutic, pathophysiologic, or other scientific evidence. - applies primarily to therapeutic intervention trials
7 Circulation Proof of concept 2. Prospective validation 6 steps to be completed 3. Incremental value 4. Clinical utility, reclassification? 5. Clinical outcomes. Reduction translates to less CV events 6. Cost-effectiveness
8 Carotid-femoral pulse wave velocity: the Gold standard for the measurement of aortic stiffness Laurent S et al. Eur Heart J 2006 L dp PWV. t. Bramwell and Hill, 1922 V dv Pulse wave velocity is the speed (4-12 m/sec) with which the pressure wave, generated by cardiac ejection, is propagated along the arterial tree
9 Carotid-femoral pulse wave velocity: the Gold standard for the measurement of aortic stiffness the «foot-to-foot method» Laurent S et al. Eur Heart J 2006 L dp PWV. t. V dv t L
10 Step 1: Proof of concept: Clinical conditions associated with an increased arterial stiffness Aging Menopausal status CV risk factors Lack of physical activity Obesity Smoking Hypertension Hypercholesterolemia Impaired glucose tolerance Metabolic syndrome Type 1 diabetes Type 2 diabetes Hyperhomocyteinemia High CRP level Genetic background Parental history of hypertension Parental history of diabetes Parental history of myocardial infarction Genetic polymorphisms CV Diseases Coronary Heart Disease Congestive Heart Failure Fatal stroke Primarily non CV diseases End-stage renal disease (ESRD) Moderate chronic kidney disease Rheumatoid arthritis Systemic vasculitis Systemic lupus erythematosus
11 AHA Guidelines: Phases of evaluation of a novel risk marker 1. Proof of concept 2. Prospective validation Arterial stiffness 1.00 Hlatky MA et al. Circulation 2009 Arterial stiffness and total mortality in 1980 hypertensives Low PWV Survival /- 0.70? Kaplan-Meier P< Follow-up (years) Medium PWV High PWV Laurent S et al., Hypertension 2001
12 Meta-analysis of the predictive value of aortic stiffness (carotid-femoral PWV) for CV events 17 studies, 15,877 subjects, FU 7.7 yrs Vlachopoulos et al. JACC 2010 Total CV events CV mortality All-cause mortality RR 1.47 [ ] RR 1.47 [ ] RR 1.42 [ ] RR for 1 SD
13 Meta-analysis in individual data: independent predictive value of aortic stiffness for CV events (16,358 subjects) Age-specific HRs for CVD, per 1SD increase in log cf-pwv Y Ben Schlomo et al. ARTERY 11, Oct 2011 Category ES (95% CI) Age_Group <50 years years years >70 years 1.83 (1.33, 2.52) 1.67 (1.40, 1.99) 1.37 (1.17, 1.61) 1.25 (1.09, 1.43) Hazard Ratio (95% CI) 14 studies including 16,358 subjects with 1700 combined CVD events. z-scores of log transformed cf-pwv (pooled SD = 3.3m/s). Higher predictive value in younger subjects: (p-value for trend = ).
14 99 patients (63±12 yrs) with acute ischemic stroke. PWV measured at 7 days. PWV = dd/t x 0.8 Functional recovery after stroke measured at 90 days using the modified Rankin scale. Multivariate analysis Gasecki et al. Stroke 2012 Age (10 years) NIHSS Previous stroke P=0.067 P=0.010 P=0.049 cf-pwv ( 9.4 m/s) P=0.021 OR Reduces fonctional outcome Increases functional outcome
15 Aortic stiffness measurement improves the prediction of asymptomatic CAD in Stroke/TIA patients beyond classical CV risk factors Calvet D et al. Int J Stroke 2012, pending revision 300 patients (45-75 yrs) with non cardioembolic stroke or TIA and no prior history of CAD 64-section CT coronary angiography (asymptomatic CAD = at least one stenosis 50%) PWV = dd/t x 0.8, Multivariate analysis FRS-predicted 10 years risk of CHD (%) < 10% 10-19% P< % Severity of cervicocephalic stenosis No atherosclerosis < 50% stenosis P= % stenosis cf-pwv (m/s) 10 m/s P=0.018 > 10 m/s Adjusted OR
16 Aortic stiffness predicts CV outcome independently of other risk factors in CKD patients NEPHROTEST cohort, n=439 CKD (stage 2-5), mean age 59.8 yrs GFR measured with 51 Cr-EDTA; mean FU = 4.7 years PWV= dd/t CV events= CV deaths, non fatal MI, coronary revascularization, and stroke Statistical analysis: Fine and Gray competing risks models Karras et al. Hypertension 2012, pending revision cf-pwv (1 SD=3.4 m/s) mgfr (10 ml/min/1.73 m²) Age (10 years) SBP (10 mmhg) Diabetes (no/yes) Active smoking (no/yes) History of CV events P=0.021 P= P=0.11 P=0.54 P=0.24 P=0.071 P= RR Decreases risk Increases risk
17 Aortic stiffness predicts CV outcome after renal transplantation, independently of other risk factors (age, gender, CRP) Verbecke et al. Hypertension 2011 n=512 renal transplant recipients mean FU = 5 years PWV= dd/t x 0.8 CV events= MI, coronary revascularization, acute pulmonary oedema, stroke, TIA, revascularization for PAD or aortic aneurysm, and sudden death PWV CAI CAP CAP= central augmentation pressure CAI = central augmentation index
18 The independent predictive value of aortic stiffness has been demonstrated for various outcomes in various populations Outcomes Populations - Total mortality - CV mortality - Coronary events - Asymptomatic CAD - Stroke - Functional outcome after stroke - Onset of dialysis - Onset of hypertension - - general population - elderly - hypertensives - diabetics (T2D) - CAD - after acute stroke - stroke/tia - chronic kidney disease (CKD): moderate, severe, ESRD - renal transplant recipients -
19 AHA Guidelines: Phases of evaluation of a novel risk marker 1. Proof of concept 2. Prospective validation 3. Incremental value vs SCORE, FRS Arterial stiffness +/-? Hlatky MA et al. Circulation 2009 C statistics
20 AHA Guidelines: Phases of evaluation of a novel risk marker 1. Proof of concept Arterial stiffness Hlatky MA et al. Circulation 2009 COPENHAGEN study: additive predictive value of PWV to SCORE 2. Prospective validation 3. Incremental value vs SCORE, FRS +/ Sehestedt et al. Eur Heart J 2010 LVH Plaque PWV>12 m/s * UACR>90th? SCORE > 5% SCORE < 5%
21 AHA Guidelines: Phases of evaluation of a novel risk marker 1. Proof of concept 2. Prospective validation 3. Incremental value vs SCORE, FRS 4. Clinical utility - Reclassification Arterial stiffness +/-? Hlatky MA et al. Circulation 2009 Framingham study Mitchell et al. Circulation % of intermediate risk individuals were reclassified into higher risk for CV events, when PWV was added to standard CV RF.
22 AHA Guidelines: Phases of evaluation of a novel risk marker 1. Proof of concept 2. Prospective validation 3. Incremental value vs SCORE, FRS 4. Clinical utility - Reclassification Arterial stiffness +/-? Hlatky MA et al. Circulation 2009 Framingham study Mitchell et al. Circulation % of intermediate risk individuals were reclassified into higher risk for CV events Meta-analysis in individual data Ben Schlomo et al. in preparation 19% of intermediate risk individuals were reclassified into higher or lower quartiles of risk for CHD (p<0.001) 22% were reclassified for stroke outcomes respectively (both p<0.001)
23 AHA Guidelines: Phases of evaluation of a novel risk marker 1. Proof of concept 2. Prospective validation Arterial stiffness Hlatky MA et al. Circulation 2009 Framingham study Mitchell et al. Circulation % of intermediate risk individuals were reclassified into higher risk for CV events 3. Incremental value vs SCORE, FRS 4. Clinical utility - Reclassification Nephrotest cohort +/- Karras et al. Hypertension, submitted 29 % of patients were reclassified into lower or higher risk for all-cause? mortality Meta-analysis in individual data Ben Schlomo et al. in preparation 19% of intermediate risk individuals were reclassified into higher or lower quartiles of risk for CHD (p<0.001) 22% were reclassified for stroke outcomes respectively (both p<0.001)
24 2013 ESH-ESC Guidelines for the management of hypertension A novel cut-off value of PWV for the prediction of CV events Subclinical organ damage Electrocardiographic LVH (Sokolow-Lyon > 38 mm; Cornell > 2440 mm*ms) or Echocardiographic LVH (LVMI M 125 g/m 2, W 110 g/m 2 ) Carotid wall thickening (IMT > 0.9 mm) or plaque Carotid-femoral pulse wave velocity > 12 m/s >10 m/s # 12 m/s x 0.8 Ankle/Brachial BP index < 0.9 Slight increase in plasma creatinine: M: mol/l ( mg/dl); W: mol/l ( mg/dl) Low estimated glomerular filtration rate (< 60 ml/min/1.73m 2 ) or creatinine clearance (< 60 ml/min) Microalbuminuria mg/24h or albumin-creatinine ratio: 17 (M); 25(W) mg/g creatinine
25 Metrics of cf-pwv: standardisation of methods PWV = Distance / t Common carotid Distance (aortic pathway at MRI) should be Sternal notch L car-ster - either direct distance x or substracted distance = L ster-fem - L car-ster Direct distance Vermeersch S et al. J Hypertens 2009 Boutouyrie P et al. Eur Heart J 2010 Van Bortel et al. J Hypertens 2012 L subtracted L ster-fem Common femoral
26 Nomal and reference values for aortic stiffness Reference Value for Arterial Stiffness Collaboration subjects (PWV=dD/t x0.8) Boutouyrie, Vermeersch et al. Eur Heart J PWV m/s PWV m/s 10 m/s corresponds to the 90 th percentile of the years decade yrs yrs Reference values Normal values 8,400 untreated subjects with CV risk factors and no T2D 1,344 healthy subjects with no CV risk factors
27 AHA Guidelines: Phases of evaluation of a novel risk marker 1. Proof of concept 2. Prospective validation 3. Incremental value vs SCORE, FRS 4. Clinical utility - Reclassification 5. Clinical outcomes. The reduction in aortic stiffness translates to the reduction in CV events Arterial stiffness +/-? Hlatky MA et al. Circulation 2009
28 Clinical outcome study: the SPARTE study Laurent et al. Hypertension 2012 Guidelines driven therapeutic strategy French Ministry of Health, French Foundation for Research in Hypertension hypertensive patients per group Arterial stiffness driven i.e patients therapeutic strategy FU: 4 years, PROBE design 40 investigation centers in France Inclusion criteria: Medium to very-high added CV risk (ESH 2007) and no T2D 10 yrs risk of CV morbidity-mortality (Framingham) >15 % (median CV risk: 20%) Primary end-point = combined end-point (median CV risk: 10% per year) stroke+mi+angioplasty+cabg+pad (angioplasty, bypass,amputation)+chf hosp.+af+aortic dissection+doubling of creatinin+esrd+sudden death Arterial stiffness driven therapeutic strategy: high recommended dose of ACEI or ARB, aldosterone blockers, CCB+ARB combination, vasodilating BB Expected nb of events: 480 vs 600
29 AHA Guidelines: Phases of evaluation of a novel risk marker Arterial stiffness Hlatky MA et al. Circulation Proof of concept 2. Prospective validation 3. Incremental value vs SCORE, FRS 4. Clinical utility - Reclassification 5. Clinical outcomes. The reduction in aortic stiffness translates to the reduction in CV events 6. Cost-effectiveness +/-?
30 Conclusion: arterial stiffness for improving risk prediction 1. Carotid-femoral PWV is a direct method for measuring aortic stiffness 2. cf-pwv measurement is a simple and robust method, easy to implement in clinical practice 3. cf-pwv has demonstrated an added predictive value for CV events in various populations, beyond ESC-SCORE, ESH-ESC Risk Chart, and Framingham risk score 4. cf-pwv is listed among subclinical organ damage by the ESH-ESC Guidelines for the management of hypertension 5. The cut-off value is 10 m/s for the prediction of CV events 6. Its value as surrogate end-point remains to be demonstrated by therapeutic intervention trials
31 Artery th 20 th October 2012 Tech Gate Vienna, Austria Endorsed by: Supported by:
32 Normalization of arterial stiffness 1. Through the reduction of BP preferentially without beta-blockers 2. Through mechanisms independent of acute BP lowering - targeting long-term arterial remodeling (several years ) - using drugs preferentially acting on fibrosis, collagen, and extra-cellular matrix In clinical practice: - highest recommended doses of RAAS blockers - combinations of RAS blockers + CCB (central PP) - ACEI, ARB, aldosterone antagonists (spironolactone, eplerenone) - using nitrates and NO donors 3. Through intensified intervention on other CV risk factors - Anti-platelet, lipid-lowering, and anti-diabetic drugs when indicated - Physical exercise, weight reduction, salt reduction, alcohol
33 cf Pulse Wave Velocity (m/s) Long-term normalization of aortic stiffness Changes in PWV, in 97 hypertensives during a 5.3 yrs FU Ait Oufella et al. J Hypertens ± 0.06 m/s/yr, P<0.001 T0 T1 T2 2.9 ± 1.2 yrs 5.3 ± 1.3 yrs PWV 14.2 ± 4.2 m/s 11.3 ± 2.7 m/s 11.0 ± 2.4 m/s MBP 93 ± 10 mmhg 91 ± 9 mmhg 89 ± 8 mmhg
34
35 Clinical outcome study Guidelines driven therapeutic strategy Arterial stiffness driven therapeutic strategy P<0.001 Guidelines driven Arterial stiffness driven? Pletcher MJ et al. Circulation 2011
How clinically important are the results of the large trials in hypertension?
How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationEstimated Pulse Wave Velocity Calculated from Age and Mean Arterial Blood Pressure
Received: August 19, 2016 Accepted after revision: November 4, 2016 Published online: December 1, 2016 2235 8676/16/0044 0175$39.50/0 Mini-Review Estimated Pulse Wave Velocity Calculated from Age and Mean
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationTheoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D.
Theoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D. TensioMed Arterial Stiffness Centre, Budapest Heart Institute, Faculty of Medicine, University of Pécs
More informationPharmacological modulation of vascular structure and function. L. Van Bortel. Heymans Institute of Pharmacology, Ghent University
Pharmacological modulation of vascular structure and function L. Van Bortel Heymans Institute of Pharmacology, Ghent University BHC 2015 Pharmacological modulation of Endothelial function CIMT Pulse wave
More informationSubclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.
More informationEarly Detection of Damaged Organ
Early Detection of Damaged Organ Regional Cardiovascular Center, Chungbuk National University Kyung-Kuk Hwang Contents NICE guideline 2011 - Confirm the diagnosis of HT ambulatory blood pressure monitoring
More informationsurtout qui n est PAS à risque?
3*25 min et surtout qui n est PAS à risque? 2018 ESC/ESH Hypertension Guidelines 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension 28 th ESH Meeting on Hypertension and Cardiovascular
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationDisclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin
Disclosures Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Servier International, Boehringer Ingelheim Servier International,
More informationDanno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo?
Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo? Prof. Massimo Salvetti Clinica Medica University of Brescia Percieved risk Actual risk Sehestedt et al,
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationDirector of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016
The differential effect of Atherosclerosis on end organ damage in adult and elderly patients with CVRF: New Algorithm for Hypertension Diagnosis and Treatment R. Zimlichman, FAHA, FASH, FESC, FESH Chief
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationAssessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time. Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France
Assessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France The causes of Cardiovascular Diseases in CKD Systolic BP;
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationPrevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient
Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient The Issue of Primary Prevention of A.Fib. (and Heart Failure) and not the Prevention of Recurrent A.Fib. after Electroconversion
More informationWhen should you treat blood pressure in the young?
ESC Stockholm - Dilemmas in Cardiovascular Disease Prevention in the Young: 30 th August 2010 When should you treat blood pressure in the young? Bryan Williams MD FRCP FAHA FESC Professor of Medicine Department
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationDEPARTMENT OF GENERAL MEDICINE WELCOMES
DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationWhich CVS risk reduction strategy fits better to carotid US findings?
Which CVS risk reduction strategy fits better to carotid US findings? Dougalis A, Soulaidopoulos S, Cholongitas E, Chalevas P, Vettas Ch, Doumtsis P, Vaitsi K, Diavasti M, Mandala E, Garyfallos A 4th Department
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationCardiovascular Protection and the RAS
Cardiovascular Protection and the RAS Katalin Kauser, MD, PhD, DSc Senior Associate Director, Boehringer Ingelheim Pharmaceutical Inc. Micardis Product Pipeline Scientific Support Ridgefield, CT, USA Cardiovascular
More informationSession : Why do stroke patients need a cardiologist? PREVALENCE OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CEREBRAL INFARCTION
Session : Why do stroke patients need a cardiologist? PREVALENCE OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CEREBRAL INFARCTION The Asymptomatic Myocardial Ischemia in Stroke and Atherosclerotic Disease
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationCentral Pressures and Prehypertension
Central Pressures and Prehypertension Charalambos Vlachopoulos Associate Professor of Cardiology 1 st Cardiology Dept Athens Medical School Central Pressures and Prehypertension Charalambos Vlachopoulos
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationPreventing Early Vascular Ageing (EVA) and its hemodynamic changes
Translational Research 31 st October 2013, Moscow Preventing Early Vascular Ageing (EVA) and its hemodynamic changes Peter M Nilsson, MD, PhD Department of Clinical Sciences Lund University University
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationΗ σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις
Η σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις Ελένη Τριανταφυλλίδη Επιμελήτρια Α Β Πανεπιστημιακή Καρδιολογική Κλινική Αττικό Νοσοκομείο
More informationArterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly. Piotr Jankowski
Arterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly Piotr Jankowski I Department of Cardiology and Hypertension CM UJ, Kraków, Poland piotrjankowski@interia.pl Vienna,
More informationArterial function and longevity Focus on the aorta
Arterial function and longevity Focus on the aorta Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Secrets of longevity Secrets of longevity Unveiling
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationDonation from Old Living Donors How safe is it? Safe for recipient or donor?
Donation from Old Living Donors How safe is it? Safe for recipient or donor? Pr Lionel Rostaing Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation CHU Grenoble Alpes France lrostaing@chu-grenoble.fr
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationPrevention of Cardiovascular Disease
Save Thais from Heart Diseases 2019 Prevention of Cardiovascular Disease Orawan Anupraiwan, MD. Central Chest Institute of Thailand ASCVD Prevention Pyramid Risk categories Very high-risk High-risk Documented
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationEffects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France
Effects of Renin-Angiotensin System blockade on arterial stiffness and function Gérard M. LONDON Manhès Hospital Paris, France Determinants of vascular overload (afterload) on the heart Peripheral Resistance
More informationDisclosure of Relationships
Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationAn Epidemiological Overview
An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationClinical application of Arterial stiffness. pulse wave analysis pulse wave velocity
Clinical application of Arterial stiffness pulse wave analysis pulse wave velocity Arterial system 1. Large arteries: elastic arteries Aorta, carotid, iliac, Buffering reserve: store blood during systole
More informationAn Epidemiological Overview
An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationBackground. Metabolic syndrome T2DM CARDIOVASCULAR DISEASE. Major Unmet Clinical Need. Novel Risk Factors. Classical Risk Factors LDL-C.
The effect of metabolic syndrome for left ventricular geometry, arterial stiffness and carotid intima-media thickness in Korean general population Result from Atherosclerosis RIsk of Rural Area in Korea
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationΠρώιμη αγγειακή γήρανση στην υπέρταση: διάγνωση και αντιμετώπιση
Πρώιμη αγγειακή γήρανση στην υπέρταση: διάγνωση και αντιμετώπιση Χαράλαμπος Βλαχόπουλος 1 η Καρδιολογική Κλινική Πανεπιστημίου Αθηνών Ιπποκράτειο Γ.Ν.Α. Οι προβλεπόμενες αρτηριακές αλλαγές με βάση την
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationTHE ESC/EAS LIPID GUIDELINES IN THE ELDERLY
THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY Alberico L. Catapano alberico.catapano@unimi.it Alberico L. Catapano Potential Conflict Of Interest Prof. Catapano has received honoraria, lecture fees, or research
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationE.Ritz Heidelberg (Germany)
Predictive capacity of renal function in cardiovascular disease E.Ritz Heidelberg (Germany) If a cure is not achieved, the kidneys will pass on the disease to the heart Huang Ti Nei Ching Su Wen The Yellow
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationPreventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia
Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationWhich method is better to measure arterial stiffness; augmentation index, pulse wave velocity, carotid distensibility? 전북의대내과 김원호
Which method is better to measure arterial stiffness; augmentation index, pulse wave velocity, carotid distensibility? 전북의대내과 김원호 Arterial stiffness Arterial stiffness is inversely related to arterial
More informationArterial Pressure in CKD5 - ESRD Population Gérard M. London
Arterial Pressure in CKD5 - ESRD Population Gérard M. London INSERM U970 Paris 150 SBP & DBP by Age, Ethnicity &Gender (US Population Age 18 Years, NHANES III) 150 SBP (mm Hg) 130 110 80 Non-Hispanic Black
More informationNew Antihypertensive Strategies to Improve Blood Pressure Control
New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University
More informationInsidie del binomio iperuricemia e rischio CV
Insidie del binomio iperuricemia e rischio CV Claudio Borghi, FESC, FAHA Department of Medical and Surgical Sciences University of Bologna, Bologna, Italy Claudio Borghi Potential conflicts of interest
More informationDepartments of Cardiology and Vascular Surgery Michaelidion Cardiac Center University of Ioannina, Greece
Departments of Cardiology and Vascular Surgery Michaelidion Cardiac Center University of Ioannina, Greece ARGYRIS Vassilis, PEROULIS Michalis, MATSAGKAS Miltiadis, BECHLIOULIS Aris, MICHALIS Lampros, NAKA
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationThe organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.
The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. Leviticus Rabba 3 Talmud Berochoth 6 1 b Outline &
More informationHeart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial
Heart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial Sripal Bangalore, MD, MHA, Chuan-Chuan Wun, PhD, David A DeMicco, PharmD,
More informationCentral hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction
Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction N.Skliros, N.Ioakeimidis, D.Terentes-Printzios, C.Vlachopoulos Cardiovascular Diseases and Sexual Health
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationPost Hoc Analysis of the PARADIGM Heart Failure Trial:
Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming
More informationJ-curve Revisited. An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial
J-curve Revisited An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial Sripal Bangalore, MD, MHA, Franz H Messerli, MD, Chuan-Chuan Wun, PhD, Andrea L. Zuckerman,
More informationThe ESC Registry on Chronic Ischemic Coronary Disease
EURObservational Research Programme The ESC Registry on Chronic Ischemic Coronary Disease Prof. Fausto J. Pinto, FESC, FACC, FASE, FSCAI Immediate Past-President, ESC University Hospital Sta Maria University
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationThe earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
More information